Definitive Additional Materials

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

Filed by the Registrant   x                             Filed by a Party other than the Registrant  ¨

Check the appropriate box:

 

¨   Preliminary Proxy Statement
¨   Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨   Definitive Proxy Statement
x   Definitive Additional Materials
¨   Soliciting Material Pursuant to §240.14a-12

Alliance HealthCare Services, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x   No fee required.
¨   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

 

   

 

  (2)  

Aggregate number of securities to which transaction applies:

 

 

   

 

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

 

   

 

  (4)  

Proposed maximum aggregate value of transaction:

 

 

   

 

  (5)   Total fee paid:
   
   

 

¨   Fee paid previously with preliminary materials.
¨   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount Previously Paid:

 

 

   

 

  (2)  

Form, Schedule or Registration Statement No.:

 

 

   

 

  (3)  

Filing Party:

 

 

   

 

  (4)  

Date Filed:

 

 

   

 

 

 

 

ALLIANCE HEALTHCARE SERVICES, INC.

100 Bayview Circle, Suite 400

Newport Beach, CA 92660

 

 

ADDITIONAL MATERIAL FOR PROXY STATEMENT

DATED MAY 2, 2012

On April 28, 2012, Paul S. Viviano, Chairman of our Board of Directors and President and Chief Executive Officer, notified our Board of Directors that he will resign as President and Chief Executive Officer in June 2012, with the exact date to be determined. Mr. Viviano will remain on our Board of Directors but will resign as Chairman. Mr. Viviano is leaving the company to accept the position of Associate Vice Chancellor for Health Sciences at the University of California, San Diego and Chief Executive Officer of the UCSD Health System.

On April 28, 2012, our Board of Directors appointed Larry C. Buckelew, who has served as an independent member of our Board of Directors since January 2009, as Chairman of our Board of Directors and interim Chief Executive effective upon Mr. Viviano’s resignation in June 2012. Mr. Buckelew served as president and chief executive officer of Gambro Healthcare, Inc. from November 2000 through October 2005. From April 2000 to November 2000, he served as president of Gambro Healthcare/USA. Mr. Buckelew began his career with American Hospital Supply Corporation (AHSC) in 1975 and served as an executive with AHSC and later Baxter International, Inc. following their merger in November 1985. He has also held executive and management positions with Sunrise Medical, Inc., Teleflex, Inc. and Surgical Services, Inc.

In addition, our Board of Directors has appointed Michael J. Shea as our new Chief Operating Officer effective June 4, 2012. From July, 2008 until joining Alliance, Mr. Shea was a senior vice president at DaVita, Inc., a publicly held renal care company with more than $7 billion in revenues, operating 1800 outpatient clinics, and 850 hospitals. Mr. Shea was responsible for DaVita’s operations in California, Nevada, and Arizona, as well as a large hospital services division. Prior to DaVita, from July, 2004 until June, 2008, Mr. Shea was the senior vice president of business development and marketing at TeamHealth, an outsourced physician services company that contracted with hospitals and physician groups, with revenues exceeding $1 billion annually.

On April 30, 2012, Richard J. Hall informed our Board of Directors that he will resign as President of our Radiation Oncology Division, effective May 28, 2012. Mr. Hall is leaving the company to become Chief Executive Officer of a non-competing, New York-based company.